glp 1 receptor agonists canada GLP-1 Agonist Market Size, Share, Growth, 2034 Frontiers | GLP-1 Receptor Agonists:
Description
Governments looking to reduce the costs of healthcare and boost economic productivity also need to tread carefully when encouraging the use of GLP-1 drugs in people with obesity without addressing the wider socio-economic challenges patients face as well as the problems posed by the rise in ultra-processed food and poor provision of physical exercise facilities
If you purchase through links in this article, a commission may be earned at no additional cost to you
PYY, Peptide YY
References Abdelaal M, le Roux CW, Docherty NG
